Evidence against a vasopressor role of ADH in malignant DOC-salt hypertension

Clin Exp Hypertens A. 1985;7(10):1457-70. doi: 10.3109/10641968509073603.

Abstract

To investigate the possible role of vasopressin (VP) in the maintenance of DOC-salt hypertension the effect of two VP pressor antagonists on mean arterial pressure and the pressor responsiveness to exogenous VP were studied in conscious, freely moving rats with malignant DOC-salt hypertension. Intravenous injections of either 20 micrograms/kg of dP Tyr(Me)AVP or 10 micrograms/kg of d(CH2)5Tyr(Me)AVP had no significant effect on mean arterial pressure and heart rate, although both antagonists almost completely abolished the pressor response to VP. Furthermore, the animals with DOC-salt hypertension exhibited decreased pressor responsiveness to exogenous VP. The present findings strongly suggest that VP is not essential as a pressor hormone for maintaining blood pressure in malignant DOC-salt hypertension.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Arginine Vasopressin / analogs & derivatives*
  • Arginine Vasopressin / pharmacology
  • Desoxycorticosterone / toxicity
  • Dose-Response Relationship, Drug
  • Female
  • Hypertension, Malignant / physiopathology*
  • Rats
  • Sodium Chloride / toxicity
  • Vasopressins / administration & dosage
  • Vasopressins / antagonists & inhibitors
  • Vasopressins / physiology*

Substances

  • Vasopressins
  • Arginine Vasopressin
  • Desoxycorticosterone
  • Sodium Chloride
  • argipressin, deaminopenicillamine(1)-O-methyl-Tyr(2)-
  • vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-